IP Library Granted Patent US 8,501,701
Granted Patent B2
US 8,501,701 · App. 11/598,812 · Granted Aug 6, 2013

Use of lipid conjugates in the treatment of disease

Inventors: Saul Yedgar (Jerusalem, IL); Moshe Ligumski (Jerusalem, IL); Miron Krimsky (Jerusalem, IL)
Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,501,701
App. No.
11/598,812
Granted
Aug 6, 2013
Kind
B2
Abstract

The invention relates to methods of use for compounds in treating, reducing the incidence, reducing the severity or pathogenesis of an intestinal disease or condition in a subject, including, inter alia, inflammatory bowel disease, Crohn's disease, ulcerative colitis, or a combination thereof.

Claims (19)

1. A method for the therapeutic treatment of an intestinal disease or disorder in a subject suffering from said intestinal disease or disorder, comprising administering to the subject suffering from said intestinal disease or disorder a composition comprising a compound represented by the structure of the formula:

wherein

R 1 and R 2 each is palmitoyl or myristoyl;

Y is nothing;

X is a hyaluronic acid; and

n is a number from 1 to 1000,

wherein said intestinal disease or disorder is an inflammatory bowel disease selected from the group consisting of Crohn's Disease and ulcerative colitis.

2. A method for the therapeutic treatment of an intestinal disease or disorder in a subject suffering from said intestinal disease or disorder, comprising administering to the subject suffering from said intestinal disease or disorder a composition comprising a compound represented by the structure of the formula:

wherein

R 1 and R 2 each is palmitoyl or myristoyl;

Y is nothing;

X is carboxymethylcellulose; and

n is a number from 1 to 1000,

wherein said intestinal disease or disorder is an inflammatory bowel disease selected from the group consisting of Crohn's Disease and ulcerative colitis.

3. The method of claim 1 or 2 , wherein said compound comprises dipalmitoyl phosphatidylethanolamine or dimyristoyl phosphatidylethanolamine.

4. The method of claim 1 or 2 , wherein said inflammatory bowel disease is Crohn's Disease.

5. The method of claim 1 or 2 , wherein said inflammatory bowel disease is ulcerative colitis.

6. The method of claim 1 or 2 , wherein said compound is administered at a dose of 5 mg/ml.

7. The method of claim 1 or 2 , wherein said compound is administered at a dose of 20 mg/ml.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2018
From: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD
To: YEDGAR, SAUL
Reel/Frame 046006/0942 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2010
From: YEDGAR, SAUL; LIGUMSKI, MOSHE; KRIMSKY, MIRON
To: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
Reel/Frame 024903/0223 →
Continuity (5)
Continuation In Part 10952496 · Sep 29, 2004
Continuation In Part 10790182 · Mar 2, 2004
Continuation In Part 09756765 · Jan 10, 2001
Provisional Application 60174907 · Jan 10, 2000
Related Publication 20070117779A1 · May 24, 2007